Last reviewed · How we verify
NCT06707506
Atrial Fibrillation Risk After Miniinvasive Mitral Valve Repair
trial in Mitral Regurgitation in 114 participants. Completed in 1 August 2024.
30 November 2023
Quick facts
| Lead sponsor | Nemocnice AGEL Trinec-Podlesi a.s. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 114 |
| Start date | 1 January 2014 |
| Primary completion | 30 November 2023 |
| Estimated completion | 1 August 2024 |
Conditions studied
- Mitral Regurgitation — all drugs for Mitral Regurgitation →
- Computed Tomography — all drugs for Computed Tomography →
- Atrial Fibrillation — all drugs for Atrial Fibrillation →
Sponsor
Nemocnice AGEL Trinec-Podlesi a.s.
Who can join
Adults 19 to 110, any sex, with Mitral Regurgitation or Computed Tomography. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This retrospective cohort study investigates how CT-derived tissue quality parameters, serving as markers of metabolic status, predict post-operative atrial fibrillation risk in patients undergoing minimally invasive mitral valve surgery. The study leverages established associations between adipose tissue characteristics and metabolic dysfunction to explore their potential role in post-surgical arrhythmogenesis.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Post-Operative Atrial Fibrillation: Novel Predictive Value of CT-Derived Adipose Tissue Density in Minimally Invasive Mitral Surgery.
Pekar M, Vician D, Jiravsky O, Jiravska Godula B, et al · · 2025 · PMID 41511103
Verify or expand the search:
- PubMed search for NCT06707506
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Mitral Regurgitation
Currently open trials in the same condition.
- NCT07450911 — A Clinical Study Evaluating the Replacement of the Native Mitral Valve Using the ReValve System · Phase 1 · recruiting
- NCT07366723 — The Role of cardIac magNeTic rEsonance in surGical Decision Making in Patients With Severe pRimAry miTral rEgurgitation · NA · active not recruiting
- NCT07007143 — STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication fo · Phase 4 · recruiting
- NCT07108907 — Outcome Registry and Assessment of New Edge-to-Edge Repair · recruiting
- NCT06901466 — STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for O · Phase 4 · recruiting
Other Nemocnice AGEL Trinec-Podlesi a.s. trials
Trials by the same sponsor.
- NCT07433309 — CT Body Composition as Predictor of Exercise Therapy Outcome in Peripheral Arterial Disease · not yet recruiting
- NCT06539416 — Mixed Reality in MitraClip Implantation: Preliminary Case Series · recruiting
- NCT05148923 — Comparison of Two DCCV Algorithms - Rational Versus Maximum Fixed Energy · NA · completed
- NCT05672160 — Overal Survival After TAVI According to Sarcopenia · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06707506 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nemocnice AGEL Trinec-Podlesi a.s.
- Last refreshed: 27 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06707506.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing